The high expression of classical oncogenes EGFR, TP53, and KRAS in the C3 group may suggest that targeting these classical oncogenes in KIRC patients with high expression of Purinergic genes may lead to a positive effect on tumor treatment (Figure 3E). This evidence concerns the gene EGFR and neoplasm.